Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1537712 | 0.85 | ELANE (0.37) | ALDH1A1DGAT1PRKCAELANE | |
| SCHEMBL15226245 | 0.79 | DGAT1 (0.34) | ALDH1A1DGAT1 | |
| SCHEMBL65267 | 0.78 | ELANE (0.40) | ALDH1A1DGAT1PRKCAELANE | |
| SCHEMBL8367894 | 0.76 | ALDH1A1 (0.35) | ALDH1A1DGAT1 | |
| SCHEMBL7563019 | 0.76 | DGAT1 (0.36) | ALDH1A1DGAT1PRKCAELANE | |
| SCHEMBL9524075 | 0.76 | ELANE (0.32) | ELANE | |
| SCHEMBL10017912 | 0.76 | DGAT1 (0.41) | DGAT1ELANESMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL25421893 | 0.76 | ELANE (0.39) | ALDH1A1DGAT1PRKCAELANE | |
| SCHEMBL7026388 | 0.76 | ELANE (0.39) | ALDH1A1DGAT1PRKCAELANE | |
| SCHEMBL15139 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014022752-A1 | MACROCYCLES AS PIM INHIBITORS | AMGEN INC. (US) | 2014-02-06 | — | — | WO | claimed |
| CN-103333354-A | Preparation method of novel anhydrous proton conductive material used for fuel cell | UNIV ZHENGZHOU | 2013-10-02 | — | — | CN | claimed |
| CN-1962666-A | Cepham antibiotics and its intermediate preparation method | JIANGSU SIMCERE PHARMACEUTICAL (CN) | 2007-05-16 | — | — | CN | claimed |
| CN-114080380-B | 2- (2, 4, 5-Trimethylcyclohex-2-en-1-yl) acetaldehyde and derivatives and their use as fragrance chemicals | 巴斯夫欧洲公司 | 2024-05-28 | — | — | CN | disclosed |
| EP-3997057-A1 | 2-(2,4,5-TRIMETHYLCYCLOHEX-2-EN-1-YL)ACETALDEHYDE AND DERIVATIVES AND THEIR USE AS AROMA CHEMICALS | BASF SE (DE) | 2022-05-18 | — | — | EP | disclosed |
| CN-114080380-A | 2- (2,4, 5-trimethylcyclohex-2-en-1-yl) acetaldehyde and derivatives and their use as fragrance chemicals | 巴斯夫欧洲公司 | 2022-02-22 | — | — | CN | disclosed |
| US-9575062-B2 | Zwitterion-containing acridinium compounds | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9487480-B2 | Zwitterionic reagents | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160274094-A1 | ZWITTERIONIC REAGENTS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-9353056-B2 | — | — | 2016-05-31 | — | — | US | disclosed |
| US-20140295575-A1 | ZWITTERION-CONTAINING ACRIDINIUM COMPOUNDS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2014-10-02 | — | — | US | disclosed |
| WO-1992006085-A1 | PHENYLPYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-04-16 | — | — | WO | disclosed |
| WO-1991017987-A1 | PHENOL AND PYRIDINOL DERIVATIVES AS PHARMACEUTICALS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1991-11-28 | — | — | WO | disclosed |
| US-4797414-A | Naphthothiophene derivatives and their use as respiratory enhancing agents | ZYMA SA (CH) | 1989-01-10 | — | — | US | disclosed |
| EP-0278911-A1 | Bicyclic beta-lactam carboxylic acids | CIBA-GEIGY AG (CH) | 1988-08-17 | — | — | EP | disclosed |
| EP-0277917-A2 | Certain adenosine 5'-carboxamide derivatives | CIBA-GEIGY AG (CH) | 1988-08-10 | — | — | EP | disclosed |
| EP-0233154-A2 | Unsaturated amino-acids | CIBA-GEIGY AG (CH) | 1987-08-19 | — | — | EP | disclosed |
| EP-0193493-A2 | Tricyclic thieno derivatives, their preparation and pharmaceutical compositions containing them | Zyma SA (CH) | 1986-09-03 | — | — | EP | disclosed |
| EP-0139917-A1 | Pharmaceutical preparations, acylated hydrazine derivatives, methods for their preparation | CIBA-GEIGY AG (CH) | 1985-05-08 | — | — | EP | disclosed |
| EP-0033255-B1 | OXIMES DERIVED FROM ERYTHROMYCIN A, THEIR PREPARATION, THEIR APPLICATION IN PHARMACEUTICALS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160274094-A1 | ZWITTERIONIC REAGENTS | BTD, HLCS, WIZ | ALDH1A1 4381/4885DGAT1 4117/4885PRKCA 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.